Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05941949
Other study ID # PHX 1.2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 5, 2023
Est. completion date June 2024

Study information

Verified date July 2023
Source Pharmanex
Contact Adrian Lopresti, MD
Phone 61-8-9448-7376
Email adrian@clinicalresearch.com.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.


Description:

The objective of this prospective, placebo controlled, double-blinded, parallel-group study is to examine the effects of dietary supplement containing grape juice extract, astaxanthin, and vitamin E over 12 week consumption on cognitive performance and self report results based on questionnaires. Furthermore, an evaluation of general well-being, mood, markers of oxidative stress, neurogenesis (BDNF), eye health, skin health, skin carotenoid concentrations, and safety measurements will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date June 2024
Est. primary completion date January 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Health Individuals - Residing in independent living accommodations - Subjective report of memory or attention problems by answering 'yes' to the following questions: Do you have problems with your memory, attention, or concentration? - Non-smoker - Body Mass Index (BMI) between 18-35 kg/m2 - No plan to commence new treatments over the study period - Understand, willing and able to comply with all study procedures - Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the study Exclusion Criteria: - Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer's Association (NIA/AA) criteria - A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M) - Suffering from recently diagnosed or unmanaged medical conditions including but not limited to diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease, autoimmune disease, endocrine disease, or cancer/malignancy - Diagnosis of a psychiatric disease (other than mild-to moderate depression of anxiety) and/or neurological condition/disease (e.g. Parkinson's, Alzheimer's disease) - History of paralysis, stroke or seizures or head injury (with loss of consciousness) - Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibiters, or steroid medications. - Taking vitamins or herbal supplements that are reasonably expected to influence study measures - In the last 6 month, commenced or changed the dose of nutritional and/or herbal supplements that may impact on treatment outcome - Alcohol intake greater than 14 standard drinks per week - Current or 12-month history of illicit drug abuse - Pregnant women, women who are Brest feeding, or women who intend to fall pregnant - Any significant surgeries over the last year - Planned major lifestyle change in the next 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E
2 softgels per day
Placebo
2 softgels per day

Locations

Country Name City State
Australia Clinical Research Australia Duncraig Western Austrailia

Sponsors (2)

Lead Sponsor Collaborator
Pharmanex Clinical Research Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Ocular Surface Disease Index score Determine the change in Ocular Surface Disease Index score Baseline, Week 4, Week 8, Week 12
Other Change in diastolic blood pressure measurement (safety measure) Determine change in diastolic blood pressure changes using sphygmomanometer Baseline and Week 12
Other Change in systolic blood pressure measurement (safety measure) Determine change in systolic blood pressure measurement using sphygmomanometer Baseline and Week 12
Primary Change in working memory Determine change in working memory as measured by the Numeric Working Memory Test Baseline and Week 12
Primary Change in Working memory by Corsi Block tasks Determine if working memory change by doing Corsi blocks task Baseline and Week 12
Primary Change in verbal learning and memory Determine if verbal learning and memory change using total score on Rey Auditory Verbal Learning test trials 1 to 5 Baseline and Week 12
Primary Change in episodic memory Determine change in episodic memory as measured by Rey Auditory Verbal Learning Test delayed recall and computerized location learning task Baseline and Week 12
Secondary Change in accuracy of attention Determine change inaccuracy of attention as measured by the choice reaction time and digit vigilance task (percent correct) Baseline and Week 12
Secondary Change in the Everyday Memory Determine the change in the Everyday Memory Questionnaire total score Baseline, Week 4, Week 8, Week 12
Secondary Change in the Perceived Stress score Determine the change in the Perceived Stress Questionnaire total score Baseline, Week 4, Week 8, Week 12
Secondary Change in the World Health Organization score Determine the change in the World Health Organization-5 (WHO-5) score Baseline, Week 4, Week 8, Week 12
Secondary Change in oxidative stress marker Determine change in plasma malondialdehyde Baseline and Week 12
Secondary Change in plasma Tumor Necrosis Factor-alpha concentrations Determine change in plasma Tumor Necrosis Factor concentrations Baseline and Week 12
Secondary Change in marker of inflammation in the plasma Determine the change in the plasma marker (interleukin-6-alpha concentrations Baseline and Week 12
Secondary Change in plasma Brain-derived neurotropic factor concentrations Determine the change in plasma Brain-derived neurotropic factor concentrations Baseline and Week 12
Secondary Change in Skin Carotenoid Score Determine the change in Skin Carotenoid Scores using Raman spectroscopy (BioPhotonic Scanner) Baseline and Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1